[4-(3-methylpyridin-2-yl)phenyl]methanol | 364077-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [4-(3-methylpyridin-2-yl)phenyl]methanol
• 英文别名: [4-(3-methyl-2-pyridinyl)phenyl]methanol
• CAS: 364077-94-1
• 化学式: C₁₃H₁₃NO
• 分子量: 199.252
• InChiKey: BHZIXWRWYBBDHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [4-(3-methylpyridin-2-yl)phenyl]methanol 以 N,N-二甲基甲酰胺 为溶剂， 以25%的产率得到4-(3-methyl-2-pyridinyl)benzoic Acid
  参考文献：
  名称：

  Pharmaceutically active pyrrolidine derivatives as bax inhibitors

  摘要：

  本发明涉及新的取代吡咯烷衍生物的化学式(I)。所述化合物通常用作药用活性化合物。具体来说，化学式(I)的吡咯烷衍生物在治疗和/或预防神经退行性疾病、与多谷氨酸氨基酸序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病方面具有用处。所述吡咯烷衍生物显示出对细胞死亡促进子Bax和/或导致Bax激活途径的调节作用，最显著地是下调至抑制活性，并因此允许阻止细胞色素(c)的释放。本发明还涉及新的具有药用活性的取代吡咯烷衍生物，以及它们的制备方法，其中X选自O、S、CR<6>R<7>、NOR<6>、NNR<6>R<7>组成的群；A选自—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO2-、—SO2NH—；—CH2-；B是一个群—(C═O)—NR<8>R<9>或代表具有化学式(II)的杂环残基，其中Q是NR<10>、O或S；n是选自0、1或2的整数；Y、Z和E与它们连接的两个碳共同形成一个5-6成员芳香族或杂芳族环。

  公开号：

  US20030171309A1
• 作为产物：
  描述：

  2-溴-3-甲基吡啶 、 4-羟甲基苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 8.0h， 以91%的产率得到[4-(3-methylpyridin-2-yl)phenyl]methanol
  参考文献：
  名称：

  解决在一系列新的联芳基衍生物中观察到的光毒性：发现有效，选择性和口服活性的磷酸二酯酶10A抑制剂ASP9436

  摘要：

  我们合成了几种作为PDE10A抑制剂的联芳基衍生物，以防止2- [4-（{[1-甲基-4-（吡啶-4-基）-1] H-吡唑-3-基]氧基}甲基）苯基]喹啉的光毒性（1）发现联芳基的能量最小构象和共平面构象之间的能量差有助于促进联芳基化合物的光毒性潜力的预测。在3T3 NRU测试中，用N-甲基苯并咪唑取代1的喹啉环增加了这种能量差并防止了光毒性。进一步优化确定了1-甲基-5-（1-甲基-3-{[4-（1-甲基-1 H-苯并咪唑-4-基）苯氧基]甲基} -1 H-吡唑-4-基）吡啶- 2（1小时）-一（38b）。化合物38b显示出对其他PDE的良好选择性，并且在新颖的物体识别测试中，口服施用38b改善了小鼠的视觉识别记忆缺陷，剂量为0.001和0.003mg / kg。因此，ASP9436（倍半磷酸盐的38b）可用于治疗具有低光毒性风险的精神分裂症。

  DOI：

  10.1016/j.bmc.2015.04.052

文献信息

• Pharmaceutically active pyrrolidine derivatives
  申请人：——

  公开号：US20030212012A1

  公开（公告）日：2003-11-13

  The present invention is related to pyrrolidine derivatives of formula (I). Said 1 compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。
• [EN] PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS<br/>[FR] DERIVES DE LA PYRROLIDINE PHARMACEUTIQUEMENT ACTIFS COMME INHIBITEURS DE BAX
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2001074769A1

  公开（公告）日：2001-10-11

  The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating - up to an inhibitory - activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR?6R7, NOR6, NNR6R7¿; A is selected from the group consisting of -(C=O)-, -(C=O)-O-, -C(=NH)-, -(C=O)-NH-, -(C=S)-NH, -SO¿2?-, -SO2NH-; -CH2-; B is either a group -(C=O)-NR?8R9¿ or represents a heterocyclic residue having the formula (II) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及公式（I）的新取代吡咯烷衍生物。所述化合物优选用作药物活性化合物。具体而言，公式（I）的吡咯烷衍生物在神经退行性疾病、与多谷氨酸重复序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病的治疗和/或预防中有用。所述吡咯烷衍生物显示出调节性，尤其是对于细胞死亡促进剂Bax和/或导致Bax的激活途径具有下调至抑制性的活性，并因此允许阻止细胞色素（c）的释放。本发明还涉及新型药物活性取代吡咯烷衍生物以及其制备方法，其中X选自O，S，CR?6R7，NOR6，NNR6R7¿的群；A选自-(C=O)-，-(C=O)-O-，-C（=NH）-，-(C=O)-NH-，-(C=S)-NH，-SO¿2?，-SO2NH-；-CH2-；B是一个-(C=O)-NR?8R9¿基团或代表具有公式（II）的杂环残基，其中Q是NR10，O或S；n是选择的0、1或2的整数；Y、Z和E与它们所连接的2个碳一起形成一个5-6成员芳基或杂芳基环。
• [EN] PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS<br/>[FR] DERIVES PYRROLIDINE ACTIFS SUR LE PLAN PHARMACEUTIQUE UTILISES EN TANT QU'INHIBITEURS DE BAX
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2001072705A1

  公开（公告）日：2001-10-04

  The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR?6R7, NOR6, NNR6R7¿; A is selected from the group consisting of -(C=O)-, -(C=O)-O-, -C(=NH)-, -(C=O)-NH-, -(C=S)-NH, -SO¿2?2-, -SO2NH-, -CH2-,B is either a group -(C=O)-NR?8R9¿ or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式（I）的吡咯烷衍生物。所述化合物最好用作药物活性化合物。具体而言，式（I）的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示氧合胃素受体重要调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地说，所述化合物在治疗和/或预防由氧合胃素介导的疾病状态方面是有用的，包括早产、早产和痛经。本发明还涉及新的吡咯烷衍生物以及其制备方法，其中X选自CR？6R7，NOR6，NNR6R7¿组成的群；A选自-(C=O)-，-(C=O)-O-，-C（=NH）-，-(C=O)-NH-，-(C=S)-NH，-SO¿2？2-，-SO2NH-，-CH2-；B是-(C=O)-NR？8R9¿或表示具有公式（a）的杂环残基，其中Q是NR10，O或S；n是选择的整数0、1或2；Y、Z和E与它们附着的2个碳原子一起形成一个5-6成员芳香族或杂芳基环。
• Pyrrolidine oxadiazole-and thiadiazole derivatives
  申请人：——

  公开号：US20040220238A1

  公开（公告）日：2004-11-04

  The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation. (I) B is a oxadiazole or thiadiazole group. 1

  本发明涉及吡咯烷氧二唑和噻二唑衍生物，用作药物活性化合物，以及含有此类吡咯烷氧二唑衍生物的制药配方。所述吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面具有用途。特别地，本发明涉及显示出显著调节活性，特别是催产素受体拮抗剂活性的吡咯烷衍生物。更具体地，这些化合物在治疗和/或预防由催产素介导的疾病状态方面具有用途，包括早产、早产和痛经。本发明还涉及新型吡咯烷衍生物及其制备方法。(I) B是氧代二唑或噻二唑基团。
• Pyrrolidine ester derivatives with oxytocin modulating activity
  申请人：——

  公开号：US20040147511A1

  公开（公告）日：2004-07-29

  The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonise the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR 6 R 7 , NOR 6 , NNR 6 R 7 ;R is selected from the group comprising or consisting of C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl. R 1 is selected from the group comprising or consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, 3-8-membered cycloalkyl, acyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl or aryl or heteroaryl group. 1

  本发明涉及使用式（I）的吡咯烷酯治疗和/或预防早产、早产和痛经。特别是，本发明涉及使用式（I）的吡咯烷酯来调节，尤其是拮抗催产素受体。本发明还涉及新型吡咯烷酯。其中，X选自CR6R7、NOR6、NNR6R7组成的群；R选自C1-C6烷基、C2-C6烯基、C2-C6炔基、饱和或不饱和的含1到3个N、O、S杂原子的3-8环脂肪环烷基、芳基、杂环芳基、C1-C6烷基芳基、C1-C6烷基杂环芳基组成的群；R1选自C1-C6烷基、C2-C6烯基、C2-C6炔基、芳基、杂环芳基、3-8环脂肪环烷基、酰基、C1-C6烷基芳基、C1-C6烷基杂环芳基，所述环烷基或芳基或杂环芳基基团可以与1-2个进一步的环烷基或芳基或杂环芳基基团融合。